Patents Assigned to Ono Pharmaceuticals Co., Ltd.
  • Novel intermediates and processes for the preparation of optically active octanoic acid derivatives
    Publication number: 20020028947
    Abstract: Novel intermediates, i.e., N-(2S-(2-propenyl)octanoyl)-(1S)-(−)-2,10-camphorsultam, N-(2S-(2-propynyl)octanoyl)-(1S)-(−)-2,10-camphorsultam and N-(2R-(2-propyl)octanoyl)-(1S)-(−)-2,10-camphorsultam; processes for the preparation of the intermediates; and processes for the preparation of optically active 2S-(2-propenyl)octanoic acid, 2S-(2-propynyl)octanoic acid and 2R-propyloctanoic acid by using the same. Optically active 2R-propyloctanoic acid equivalent or superior to that prepared by the process of the prior art in optical purity can be efficiently prepared in shorter reaction steps.
    Type: Application
    Filed: September 7, 2001
    Publication date: March 7, 2002
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventor: Hisashi Yamamoto
  • Remedies for motor dysfunction and GAPDH expression inhibitors
    Patent number: 6348488
    Abstract: Remedies for motor dysfunction and GAPDH expression inhibitors containing as the active ingredient N-[3-[N-(4-chlorophenylmethyl)carbamoyl]propanoyl]-L-prolinal. Since it has an effect of ameliorating motor dysfunction, N-[3-[N-(4-chlorophenylmethyl)carbamoyl]propanoyl]-L-prolinal is useful in treating motor dysfunction caused by trauma, infection, degeneration, ischemia, tumor, etc. Also, it is useful in treating diseases caused by apoptosis in the cerebellum, spinal nerve nucleus or conduction route due to the overexpression of GAPDH (Parkinson's diseases, Parkinson's syndrome, Huntington's disease, MJD, ALS, CHJ diseases, etc.).
    Type: Grant
    Filed: April 2, 2001
    Date of Patent: February 19, 2002
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Ryoichi Ishitani, Nobuo Katsube
  • Naphthyloxy acetic acid derivatives and a pharmaceutical composition comprising them as an active ingredient
    Patent number: 6335366
    Abstract: The naphthyloxyacetic acid derivatives of the formula (I) wherein A is H, -(alkylene)COOR1, -(alkylene)CONR2R3, -(alkylene)OH, -(alkylene)tetrazole, -(alkylene)CN; E is single bond or alkylene; G is —S—, —SO—, —SO2—, —O— or —NR4—; L is alkylene, —(CH2)m—CH═CH—(CH2)n— or —(CH2)x—CH(OH)—(CH2)y—; M is phenyl, phenyl(thio, oxy, amino), diphenylmethyl, diphenylmethyl(thio, oxy, amino), and pharmaceutical composition comprising them as an active ingradient. The compounds of the formula (I) can combine PGE2 receptor and exhibit the activity to antagonize or agonize for PGE2 receptor. Therefore, they are useful as anti-hyperlipemia, for the prevention of abortion, for analgesics, as antidiarrheals, sleep inducer, diuretic, anti-diabetes, abortient, cathartics, antiulcer, anti-gastritis or antihypertensive etc.
    Type: Grant
    Filed: January 22, 2001
    Date of Patent: January 1, 2002
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Yuuki Nagao, Kazuhiko Torisu, Nobuyuki Hamanaka
  • Intermediates and processes for the preparation of optically active octanoic acid derivatives
    Patent number: 6333415
    Abstract: Novel intermediates, i.e., N-(2S-(2-propenyl)octanoyl)-(1S)-(−)-2,10-camphorsultam, N-(2S-(2-propynyl)octanoyl)-(1S)-(−)-2,10-camphorsultam and N-(2R-(2-propyl)octanoyl)-(1S)-(−)-2,10-camphorsultam; processes for the preparation of the intermediates; and processes for the preparation of optically active 2S-(2-propenyl)octanoic acid, 2S-(2-propynyl)octanoic acid and 2R-propyloctanoic acid by using the same. Optically active 2R-propyloctanoic acid equivalent or superior to that prepared by the process of the prior art in optical purity can be efficiently prepared in shorter reaction steps.
    Type: Grant
    Filed: November 13, 2000
    Date of Patent: December 25, 2001
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventor: Hisashi Yamamoto
  • Polypeptide of protein P140 and DNAs encoding it
    Patent number: 6303320
    Abstract: The present invention is related to a novel protein p140 polypeptide which is a key protein involved in the signal transmission system of insulin; method for preparation of it; DNA encoding the polypeptide; vector derived with the DNA; host cells transformed with the vector; antibody of the polypeptide; pharmaceutical composition containing the peptide or antibody; method for the prevention and/or treatment of diabetes, which is characterized by tyrosine phosphorylation of the protein p140; agent for the prevention and/or treatment of diabetes, which is characterized by containing a compound which can tyrosine phosphorylate protein p140, as active ingredient and the screening methods of the prevention and/or treatment agent. Tyrosine phosphorylation of protein p140 is an essential step in the induction of hypoglycemia by glucose uptake.
    Type: Grant
    Filed: January 8, 1998
    Date of Patent: October 16, 2001
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Hisao Tajima, Koichiro Kitagawa, Hiroyuki Ohno
  • Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient
    Patent number: 6300514
    Abstract: Pharmaceutical composition containing aryl (sulfide, sulfoxide, sulfone) derivatives of the formula (1) and the salts thereof as active ingredient (wherein R1 is H, alkyl; R2 is COOR7, CONHOR8; E is —CONR9—, —NR9CO—, —OCO—,—COO—, —CH2—O—, —(CH2)2—, vinylene, ethynylene; J is bond, alkylene; A is H, alkyl, Ar, alkyl-OH ; R3, R4 is H, alkyl, COOR19, hydroxy, —NR20R21, Ar1 etc.); R5, R6 is H, methyl) and the novel aryl (sulfide, sulfoxide, sulfone) derivatives of the formula (I).
    Type: Grant
    Filed: January 15, 1999
    Date of Patent: October 9, 2001
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Kanji Takahashi, Tsuneyuki Sugiura
  • 11,15-O-dialkylprostaglandin E derivatives, process for producing the same, and drugs containing the same as the active ingredient
    Patent number: 6288119
    Abstract: The present invention provides 11,15-O-dialkyl prostaglandin E derivatives of formula (I) (wherein all symbols are as described in Specification), or non-toxic salts thereof or cyclodextrin clathrates thereof, processes for the preparation thereof and pharmaceutical compositions containing them as active ingredient. A compound of formula (I) binds strongly and acts on EP3 receptor which is a subtype of PGE2 receptor and therefore is useful for prevention and/or treatment of liver diseases, kidney diseases, pancreatitis, myocardial infarction etc.
    Type: Grant
    Filed: August 2, 1999
    Date of Patent: September 11, 2001
    Assignee: Ono Pharmaceuticals Co., Ltd.
    Inventors: Shuichi Ohuchida, Takayuki Maruyama
  • Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative
    Patent number: 6274609
    Abstract: In order to promote solubilization or suspension of 4-oxo-8-[4-(4-phenylbutoxy)benzoylamino]-2-(tetrazol-5-yl)-4H-1-benzopyran or its hydrate (pranlukast) in water, at least one component selected from surfactants, water-soluble cellulose derivatives and water-soluble vinyl polymers is formulated together with pranlukast. Thus, it is possible to provide an aqueous liquid pharmaceutical composition containing higher concentration of pranlukast and having good properties.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: August 14, 2001
    Assignees: Ono Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd.
    Inventors: Shinichi Yasueda, Tadashi Terai, Takahiro Ogawa, Yoshinori Ii
  • &ohgr;-Cycloalkly-prostaglandin e2 derivatives
    Patent number: 6262293
    Abstract: &ohgr;-Cycloalkyl-prostaglandin E2 derivatives of formula (I) (wherein all symbols are as defined in the description); and non-toxic salts thereof, prodrugs thereof and cyclodextrin clathrates thereof. Compounds of formula (I) strongly bind on the EP2 subtype receptor. Therefore, they are useful for prevention and/or treatment of immunological diseases (autoimmune diseases, organ transplantation etc.), asthma, abnornmal bone formation, neuronal cell death, liver damage, abortion, premature birth or retina neuropathy of glaucoma etc.
    Type: Grant
    Filed: June 23, 2000
    Date of Patent: July 17, 2001
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Kousuke Tani, Shuichi Ohuchida
  • Leukotriene B4 antagonist compounds and method for treatment
    Patent number: 6262114
    Abstract: Novel amidinophenol derivatives of formula (IB) and processes for the preparation thereof; compositions containing a compound of formula (IB) as active ingredient useful as antagonists of leukotine B4 and inhibitors of phospholipase A2 and/or trypsin; methods for preventing or treating diseases induced by phospholipase A2 and/or trypsin comprising administering to a patient a compound of formula (IB); and methods for treating diseases induced by leukotine B4 comprising administering to a patient a compound of formula (IB) or a known amidinophenol derivative of formula (IA)
    Type: Grant
    Filed: November 21, 1997
    Date of Patent: July 17, 2001
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Hisao Nakai, Koumei Kamiyasu
  • Human lysophosphatidic acid receptor and use thereof
    Patent number: 6252056
    Abstract: (1) A human lysophosphatidic acid (human LPA) receptor, (2) a method for screening an antagonist or agonist, comprising using a human LPA receptor protein, (3) an LPA inhibitor comprising the human LPA receptor, (4) a method for producing the human LPA receptor, (5) a monoclonal or polyclonal antibody against the human LPA receptor, (6) a cDNA encoding the human LPA receptor, (7) a replication or expression vector carrying the above cDNA, and (8) a host cell transformed with the above replication or expression vector.
    Type: Grant
    Filed: May 11, 2000
    Date of Patent: June 26, 2001
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Daikichi Fukushima, Shinji Nakade, Hisanori Haga
  • &ohgr;-cycloalkyl-prostaglandin E1 derivatives
    Patent number: 6235780
    Abstract: (wherein R1 is OH etc.; X is Cl, F; R2 is H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl which may be substituted; n is 0-4.), non-toxic salts thereof or cyclodextrin clathrates thereof can strongly bind on EP2 subtype receptor. Therefore, they are useful for the prevention and/or treatment of immunological diseases (autoimmune diseases, post-transplantation graft rejection etc.), asthma, abnormal bone formation, neuronal cell death, hepatopathy, abortion, premature birth or retina neuropathy (e.g. glaucoma) etc.
    Type: Grant
    Filed: July 19, 1999
    Date of Patent: May 22, 2001
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Shuichi Ohuchida, Kousuke Tani
  • Benzenesulfonamide compounds
    Patent number: 6235777
    Abstract: A benzenesulfonamide compound of the formula (I) (R1 is hydroxy, C1˜4 alkoxy, NR6R7 (each R6 and R7 is, independently, H or C1˜4 alkyl.); R2 is H, C1˜4 alkyl; R3, R4 are C1˜4 alkyl, halogen trifluoromethyl; R5 is H, C1˜4 alkyl, halogen, trifluoromethyl; Y is cis-vinylene, trans-vinylene; and the symbol (i) is single bond, double bond.), non-toxic salt thereof or cyclodextrin clathrate thereof and an antagonist of EP1 receptor which is a prostaglandin E2 receptor subtype comprising it as an active ingredient. The present invention compounds of the of the formula (I) can bind strongly to EP1 receptor which is a prostaglandin E2 receptor subtype and scarcely bind to the other receptor subtypes. Therefore, they are considered to be useful as antipyretic agents, as analgesics or as treating agent for pollakiuria having little side effect.
    Type: Grant
    Filed: May 14, 1998
    Date of Patent: May 22, 2001
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Shuichi Ohuchida, Yuuki Nagao, Takayuki Maruyama
  • Condensed piperidine compound
    Patent number: 6228866
    Abstract: A compound represented by formula (I): wherein all symbols are defined in the specification, or an acid addition salt thereof or a hydrate thereof; a process for preparing the same; and a nitrogen monoxide synthase inhibitor comprising the same as an active ingredient.
    Type: Grant
    Filed: March 13, 2000
    Date of Patent: May 8, 2001
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Naoyuki Taniguchi, Kaoru Kobayashi, Masao Naka
  • Pentanoic acid derivatives
    Patent number: 6201021
    Abstract: Formula (I) compounds: wherein R1 is alkyl substituted by fluorine(s); R2 is hydroxy, alkoxy, alkoxy substituted by phenyl, NR3R4, in which R3, R4 is (i) hydrogen, (ii) alkyl, (iii) phenyl, (iv) phenyl substituted by alkoxy or carboxyl, (v) heterocyclic ring containing nitrogen atom, (vi) alkyl substituted by phenyl, phenyl subsituted by alkoxy or carboxyl, heterocyclic ring containing nitrogen atom, (vii) the nitrogen bonded to R3 and R4, taken together is a saturated heterocyclic ring or amino acid residue; and non-toxic salts and acid addition salts thereof.
    Type: Grant
    Filed: July 23, 1996
    Date of Patent: March 13, 2001
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Shuichi Ohuchida, Kazuo Kishimoto, Narito Tateishi, Hiroyuki Ohno
  • Naphthyloxyacetic acid derivatives and a pharmaceutical composition comprising them as an active ingredient
    Patent number: 6197993
    Abstract: The naphthyloxyacetic acid derivatives of the formula (I) wherein A is H, -(alkylene)COOR1, -(alkylene)CONR2R3, -(alkylene)OH, -(alkylene)tetrazole, -(alkylene)CN; E is single bond or alkylene; G is —S—, —SO—, —SO2—, —O— or —NR4—; L is alkylene, —(CH2)m—CH═CH—(CH2)n— or —(CH2)x—CH(OH)— (CH2)y—; M is phenyl, phenyl(thio, oxy, amino), diphenylmethyl, diphenylmethyl(thio, oxy, amino), and pharmaceutical composition comprising them as an active ingradient. The compounds of the formula (I) can combine PGE2 receptor and exhibit the activity to antagonize or agonize for PGE2 receptor. Therefore, they are useful as anti-hyperlipemia, for the prevention of abortion, for analgesics, as antidiarrheals, sleep inducer, diuretic, anti-diabetes, abortient, cathartics, antiulcer, anti-gastritis or antihypertensive etc.
    Type: Grant
    Filed: November 16, 1999
    Date of Patent: March 6, 2001
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Yuuki Nagao, Kazuhiko Torisu, Nobuyuki Hamanaka
  • Sulfonylamino acid derivatives
    Patent number: 6177466
    Abstract: The present invention is related to: (i) matrix metalloproteinase inhibitors containing sulfonylamino acid derivatives of the formula (Ia): wherein R1 is hydrogen, C1-4 alkyl; R is hydrogen, C1-8 alkyl etc.; E is —CONR3—, in which R3 is hydrogen, C1-4 alkyl etc., —NR3CO—, —CO—O—, —O—CO— etc.; A is hydrogen, C1-8 alkyl, C3-7 cycloalkyl, or Ar; J is bond, C2-4 alkylene etc.; G is —(CH2)m— in which m is 2, 3 or 4, or in which R6 and R7 is hydrogen, C1-8 alkyl etc.; and non-toxic salts thereof, (ii) novel sulfonylamino acid derivatives of the formula (Ib): wherein all the symbols are the same meaning as (i); and non-toxic salts thereof, and (iii) process for the preparation of the compound of the formula (Ib). The compounds of the formula (Ia) are useful for prevention and/or treatment of diseases induced by overexpression and excess activity of MMP.
    Type: Grant
    Filed: July 29, 1996
    Date of Patent: January 23, 2001
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Katsuhito Sakaki, Hidekazu Kanazawa, Tsuneyuki Sugiura, Tohru Miyazaki, Hiroyukii Ohno
  • Tetrazole compounds and pharmaceutical agents containing such derivative
    Patent number: 6136834
    Abstract: A tetrazole derivative of formula (I) ##STR1## wherein R is H, alkyl, alkoxy, carbocyclic ring, alkyl or alkoxy substituted by carbocyclic ring;AA.sup.1 and AA.sup.2 is a bond or ##STR2## and ##STR3## respectively, or AA.sup.1 and AA.sup.2, together, may have the formula (a); ##STR4## and Y is formula (b) ##STR5## wherein the Tet ring is tetrazole; Z is alkylene, alkenylene, O, S, SO, SO.sub.2, NR.sup.26, methylene in alkylene replaced by O, S, --SO--, --SO.sub.2 -- or --NR.sup.26 --; and E is H, alkyl, or COOR.sup.27.
    Type: Grant
    Filed: June 29, 1998
    Date of Patent: October 24, 2000
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Kazuyuki Ohmoto, Makoto Tanaka, Tohru Miyazaki, Hiroyuki Ohno
  • Heterocyclic compounds
    Patent number: 6114338
    Abstract: The compounds of the formula: ##STR1## wherein Y is bond or alkylene;Z is bond, alkylene or vinylene;E is(i) 4-15 membered, unsaturated, partially saturated or fully saturated, mono or bicyclic hetero ring containing as hetero atoms, one or two nitrogen atoms, one or two oxygen atoms or one sulfur atom,(ii) 4-15 membered, unsaturated or partially saturated, mono or bicyclic carbocyclic ring, or(iii) --OR.sup.4 (in which R.sup.4 is hydrogen atom, alkyl or alkyl substituted by a hydroxy group);Cyc is benzene, pyridine or imidazole;R.sup.1 is hydrogen or alkyl;R.sup.2 is hydrogen, alkyl, alkoxy or halogen atom;R.sup.3 is hydrogen, alkyl, alkoxy or --COOR.sup.5 (in which R.sup.5 is hydrogen or alkyl);with the proviso that(1) a Cyc ring should not bond to Z through a nitrogen atom in the Cyc ring when Z is vinylene and that(2) Y is not a single bond, when E is --OR.sup.
    Type: Grant
    Filed: October 13, 1999
    Date of Patent: September 5, 2000
    Assignee: ONO Pharmaceutical Co., Ltd.
    Inventors: Sung Jai Lee, Yoshitaka Konishi, Orest Taras Macina, Kigen Kondo, Dingwei Tim Yu, Manton Rodgers Frierson, Masafumi Sugitani
  • Condensed piperidine compound
    Patent number: 6110930
    Abstract: A compound represented by formula (I): ##STR1## wherein all symbols are defined in the specification, or an acid addition salt thereof or a hydrate thereof; a process for preparing the same; and a nitrogen monoxide synthase inhibitor comprising the same as an active ingredient.
    Type: Grant
    Filed: April 8, 1998
    Date of Patent: August 29, 2000
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Naoyuki Taniguchi, Kaoru Kobayashi, Masao Naka